5e5 of anti-PSMA CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human PSMA, His Tag (Cat. No. PSA-HP2Q3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
FACS analysis of Human PSMA, Fc Tag binding to PSMA-CAR-293 cells transfected with anti-PSMA-scFv 2X105 of PSMA-CAR-293 cells transfected with anti-PSMA-scFv were stained with 100μl of 1μg/mL of Human PSMA, Fc Tag (Cat. No. PSA-H5264) and negative control protein respectively, washed and then followed by PE anti-human IgG Fc antibody and analyzed with FACS (Routinely tested).
Immobilized Human PSMA, Fc Tag (Cat. No. PSA-H5264) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human PSMA Antibody, Human IgG1 with a linear range of 0.1-2 ng/mL (QC tested).
The purity of Rat PSMA, His Tag (Cat. No. PSA-R5245) is more than 90% and the molecular weight of this protein is around 170-208 kDa verified by SEC-MALS.
Measured by its ability to hydrolyze the substrate N-acetyl-L-Asp-L-Glu into N-acetyl-L-Asp and L-Glu. The L-Glu product is measured by fluorescence after its derivatization by ortho-phthaldialdehyde. The specific activity is >300 pmol/min/μg, as measured under the described conditions (QC tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Capromab pendetide | lndium-CYT-356; Indium-111-CYT-356; CYT-356; 111In CYT-356 | Approved | Eusa Pharma | ProstaScint | United States | Prostatic Neoplasms | Cytogen | 1996-10-28 | Prostatic Neoplasms | Details |
| Piflufolastat F 18 | Approved | Johns Hopkins University | Pylarify | United States | Prostatic Neoplasms | Progenics Pharmaceuticals Inc | 2021-05-26 | Carcinoma, Renal Cell; Prostatic Neoplasms | Details | |
| Gallium GA-68 PSMA-11 | Ga-68-PSMA-11; Ga-68-PSMA | Approved | Radiomedix | Gallium Ga 68 Psma-11 | United States | Prostatic Neoplasms | University Of California, San Francisco Foundation | 2020-12-01 | Prostatic Neoplasms | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Anti-PSMA CAR T-cell therapy (TNK Therapeutics) | Phase 1 Clinical | Sorrento Therapeutics | Neoplasms | Details | |
| Gallium-68 PSMA-617 | PSMA-617-[68Ga]; 225 Ac-PSMA-617; 68Ga-PSMA-617; 68Ga-DKFZ-617; 68Ga-DOTA-PSMA-DKFZ -617; Gallium-68-PSMA-617; 68Ga-DKFZ-PSMA -617 | Clinical | Deutsches Krebsforschungszentrum, University Of Heidelberg | Prostatic Neoplasms | Details |
| P28z-CAR | P28z-CAR | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center, United States Department Of Defense | Prostatic Neoplasms | Details |
| CC-1 | CC-1 | Phase 1 Clinical | The University Of Tubingen, Deutsches Krebsforschungszentrum, Dkfz | Prostatic Neoplasms | Details |
| CART-PSMA-TGFbRDN (University of Pennsylvania) | Phase 1 Clinical | University Of Pennsylvania | Prostatic Neoplasms | Details | |
| INO-5401 | INO5401; INO-5401 | Phase 2 Clinical | Inovio | Glioblastoma; Carcinoma, Transitional Cell | Details |
| Autologous T-cell therapy (anti-PSMA-CD3), Roger Williams Medical Center | Phase 1 Clinical | Roger Williams Medical Center | Prostatic Neoplasms | Details | |
| [131I]MIP-1095 | 1095; [131I]MIP-1095; [131I]MIP-1466 | Phase 2 Clinical | Progenics Pharmaceuticals Inc | Prostatic Neoplasms | Details |
| 89Zr-DFO-huJ591 | Zr89-J591; 89Zr-DFO-J591; 89Zr-DFO-huJ591 | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center | Prostatic Neoplasms | Details |
| Df-IA2BM-Zr-89 | IAB2M; 89Zr-Df-IAB2M; Df-IA2BM-Zr-89; 64Cu-NODAGA-PSMA-Mb | Phase 2 Clinical | Imaginab | Prostatic Neoplasms; Glioma | Details |
| INO-5150 | INO-5150 | Phase 1 Clinical | Inovio | Prostatic Neoplasms | Details |
| 4SCAR-PSMA T cell therapy (Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details | |
| 68Ga-PSMA-R2 (Advanced Accelerator Applications SA) | Clinical | Advanced Accelerator Applications | Prostatic Neoplasms | Details | |
| 177Lu-PSMA-R2 | 177Lu-PSMA-R2; 177Lu-PSMA-SR6 | Phase 2 Clinical | Advanced Accelerator Applications | Prostatic Neoplasms | Details |
| Fluorine-18-CTT-1057 | CTT-1057; 18F-CTT1057; CTT-1057-18F; CTT-1057-F-18 | Phase 3 Clinical | Washington University, Cancer Targeted Technology | Carcinoma, Renal Cell; Prostatic Neoplasms | Details |
| HPN-424 | HPN-424 | Phase 2 Clinical | Harpoon Therapeutics | Prostatic Neoplasms | Details |
| 67Cu-SAR-bisPSMA (Clarity Pharmaceuticals) | Phase 2 Clinical | Prostatic Neoplasms, Castration-Resistant | Details | ||
| 64Cu-SAR-bisPSMA (Clarity Pharmaceuticals) | Phase 2 Clinical | Prostatic Neoplasms, Castration-Resistant | Details | ||
| PSMA-CART cell therapy (Shanghai Bioray Laboratory) | Phase 1 Clinical | Bioray Laboraytories Inc | Prostatic Neoplasms | Details | |
| ATL-101 (ATLAB) | J-591; MLN-591; huJ-591; muJ-591; 90Y-J591; MLN-591RL; 177Lu-J591; Lu-177-J591 | Phase 2 Clinical | Cornell University | Prostatic Neoplasms | Details |
| ARX-517 | ARX-517 | Phase 1 Clinical | Ambrx Inc | Solid tumours; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
| Acapatamab | AMG-160 | Phase 1 Clinical | Amgen Inc | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| TNB-585 | TNB-585 | Phase 1 Clinical | Teneobio | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z
